6533b834fe1ef96bd129dfd9

RESEARCH PRODUCT

Adherence and Reactogenicity to Vaccines against SARS-COV-2 in 285 Patients with Neuropathy: A Multicentric Study

Salvatore IaconoVincenzo Di StefanoPaolo AlongeClaudia VinciguerraGiammarco MilellaFrancesca CaputoPiergiorgio LasorellaGabriele NetoAntonia PignoloAngelo TorrenteAntonino LupicaPaola AjdinajAlberto FirenzeStefano TozzaFiore ManganelliAntonio Di MuzioGiuseppe PiscosquitoFilippo Brighina

subject

General NeuroscienceSARS-CoV-2 infectionCIDP COVID-19 vaccines SARS-CoV-2 infection autoimmune neuropathy hereditary neuropathy neuropathy reactogenicity vaccine hesitancy vaccine safetyreactogenicityvaccine hesitancySARS-CoV-2 infection; COVID-19 vaccines; reactogenicity; vaccine safety; vaccine hesitancy; neuropathy; autoimmune neuropathy; hereditary neuropathy; CIDPneuropathyvaccine safetyCIDPhereditary neuropathyCOVID-19 vaccineautoimmune neuropathy

description

Background: The safety of the new vaccines against SARS-CoV-2 have already been shown, although data on patients with polyneuropathy are still lacking. The aim of this study is to evaluate the adherence to SARS-CoV-2 vaccination, as well as the reactogenicity to those vaccines in patients affected by neuropathy. Methods: A multicentric and web-based cross-sectional survey was conducted among patients affected by neuropathy from part of South Italy. Results: Out of 285 responders, n = 268 were included in the final analysis and n = 258 of them (96.3%) were fully vaccinated. Adherence to vaccination was higher in patients with hereditary neuropathies compared to others, while it was lower in patients with anti-MAG neuropathy (all p < 0.05). The overall prevalence of adverse events (AEs) was 61.2% and its occurrence was not associated with neuropathy type. Being female and of younger age were factors associated with higher risk of AEs, while having an inflammatory neuropathy and steroids assumption were associated with a lower risk (all p < 0.05). Younger age, having had an AE, and COVID-19 before vaccination were factors associated with symptoms worsening after vaccination (all p < 0.05). (4) Conclusions: Patients with neuropathy showed a high level of adherence to COVID-19 vaccination. Safety of vaccines in patients with neuropathies was comparable to the general population and it was more favorable in those with inflammatory neuropathy.

yearjournalcountryeditionlanguage
2022-10-16
10.3390/brainsci12101396https://hdl.handle.net/10447/583259